Vor Biopharma Inc.VOR

Vor Biopharma Inc. is a clinical-stage biotechnology company trying to turn telitacicept, a fusion protein co-developed with RemeGen, into a global franchise for autoimmune diseases such as IgA nephropathy, Sjögren’s disease, and generalised myasthenia gravis. The drug has just secured NMPA conditional approvals in China for IgA nephropathy and Sjögren’s, a regulatory milestone that the company is billing as a step toward broader global commercialisation. Yet behind the headlines, the company’s balance sheet tells a less glamorous story: a first-quarter 2026 loss of $219.6 million on revenue of $0, an operating loss of $35.2 million, and a cash burn of $38.2 million, all on a diluted share count of 43 million. Its liabilities now exceed assets by $150.4 million, leaving shareholders with negative equity and a balance sheet that looks like a patient in need of urgent care.

The company’s operating model is simple: spend heavily on R&D, incur clinical costs, and hope that a single product can fund the journey. In the latest quarter, R&D expense was $17.6 million, while capital expenditure was a mere $48,000-hardly the sign of a company scaling up, more like one treading water. The company’s cash and equivalents stood at $169.9 million at 31 March 2026, enough to keep the lights on for roughly four quarters at current burn rates, assuming no clinical setbacks and no delays in regulatory submissions. The company’s narrative leans on telitacicept’s potential, but the filings reveal a company that is, for now, a cash-burning experiment rather than a revenue-generating business.

Vor’s filings for the quarter ending 31 March 2026 show a net loss attributable to parent of $219.6 million, operating loss of $35.2 million, and cash used in operating activities of $38.2 million. The company’s assets totalled $506.7 million, liabilities $657.2 million, and stockholders’ equity a negative $150.4 million. Diluted loss per share was $5.11 on 43.0 million shares. R&D expense was $17.6 million, capex was $48,000, and cash and cash equivalents were $169.9 million. All figures are sourced from the company’s 10-Q for the period ending 2026-03-31.

The company’s share price trades on the Nasdaq, but the evidence base here is limited to SEC filings and company disclosures. The stock’s behaviour is not addressed in this report; no valuation commentary, ranges, or trade levels are inferred or stated. The filing evidence does not provide segment revenue, guidance, or buyback data, so those items remain unproven for Vor as of this date. The only concrete developments are the NMPA conditional approvals for IgA nephropathy and Sjögren’s in China, and the ongoing global Phase 3 trials for gMG and SjD.

Vor’s most recent ownership filings include a Schedule 13D/A filed on 21 July 2026, raising ownership to 9.8% for a beneficial owner, alongside Form 4 filings by two directors on the same day. These documents are available on SEC EDGAR and provide the only current window into insider and beneficial-owner activity. The company’s 8-K dated 7 July 2026 provides background on the CEO’s prior role at Dova Pharmaceuticals, a fact that may colour perceptions of management’s commercial acumen but does not, on its own, substantiate revenue or profitability. The company’s product rail centres on telitacicept, a fusion protein targeting autoimmune diseases, with NMPA conditional approvals in China and global Phase 3 trials ongoing, but no commercial sales data are provided in the evidence set.

What would change the file next? A quarterly filing showing positive operating cash flow, the initiation of commercial sales in China, or a milestone payment from a global partner would materially shift the narrative. Until then, the company remains a clinical-stage bet with a widening equity deficit and a balance sheet that needs more than one miracle drug to fix it.